kabutan

Modalis Therapeutics Corporation(4883) Summary

4883
TSE Growth
Modalis Therapeutics Corporation
66
JPY
+12
(+22.22%)
Apr 28, 3:30 pm JST
0.41
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
63.1
Apr 28, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.21
Yield
ー%
Margin Trading Ratio
5,129.87
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
55 JPY 0.34 USD
Previous Close Apr 27
54 JPY 0.33 USD
High Apr 28, 1:01 pm
76 JPY 0.47 USD
Low Apr 28, 9:00 am
55 JPY 0.34 USD
Volume
40,860,400
Trading Value
2.81B JPY 0.02B USD
VWAP
68.64 JPY 0.43 USD
Minimum Trading Value
6,600 JPY 41 USD
Market Cap
6.10B JPY 0.04B USD
Number of Trades
4,930
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Mid
1-Year Average
367
1-Year High Jun 9, 2025
9,562
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 10,974,900
Apr 17, 2026 0 10,317,000
Apr 10, 2026 0 10,318,600
Apr 3, 2026 0 9,987,500
Mar 27, 2026 0 10,023,100
Company Profile
Modalis Therapeutics Corporation conducts research and development of gene therapy drugs using its proprietary genome editing platform. The company has a base in the United States.
Sector
Pharmaceuticals
Modalis Therapeutics Corporation utilizes its proprietary genome editing platform, centered on CRISPR-GNDM technology, to research and develop gene therapy drugs. This technology functions as a "gene switch" that can control gene expression without cutting DNA, offering higher safety compared to conventional genome editing methods. The company aims to address genetic diseases, which are often in the rare disease category and inefficient to develop using traditional drug discovery approaches, by leveraging its technological prowess. Modalis employs a hybrid business model, combining partnerships with pharmaceutical companies ("collaboration model") and in-house development ("proprietary model"). The collaboration model aims for early revenue generation, while the proprietary model targets larger future revenues. The company has several ongoing development pipelines and aims to secure licensing agreements at specific stages of development.